Matt Thomas, a research associate studying host-viral pathogen responses through RNA-seq is fascinated by the high-throughput and simplified workflow of Illumina next-generation sequencing systems. RNA sequencing provides deeper insights for the complex research they perform using small RNA, and RIP seq, moving beyond just gene expression. The quick turnaround combined with the flexibility of short and long reads on the NextSeq 500 is a real asset to their cutting-edge work in virology. Video Presenter: Matt Thomas, Research Manager University of Washington Subscribe to the Illumina video channel. http://www.youtube.com/subscription_center?add_user=IlluminaInc A global leader in DNA sequencing and array-based solutions, Illumina is dedicated to improving human health by unlocking the power of the genome.Serving customers in the research, clinical, and applied markets, Illumina technology is responsible for generating more than 90% of the world’s sequencing data.*Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, agriculture, microbiology, forensic science and beyond. *Data calculations on file. Illumina, Inc., 2015.